Paul D'Angio
Director/Board Member bei NEXIMMUNE, INC.
Vermögen: 6 244 $ am 31.03.2024
Profil
Paul D'Angio is an Independent Director at NexImmune, Inc. He was previously a Senior VP & Global Head-Technical Operations at Celgene Corp.
and a Vice President & Head-Development at Edge Therapeutics, Inc. He also served as Vice President & Head-Manufacturing at PDS Biotechnology Corp.
Mr. D'Angio received his undergraduate degree from Duquesne University of The Holy Spirit and his graduate degree from Seton Hall University School of Law.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NEXIMMUNE, INC.
0,09% | 31.10.2023 | 1 113 ( 0,09% ) | 6 244 $ | 31.03.2024 |
Aktive Positionen von Paul D'Angio
| Unternehmen | Position | Beginn |
|---|---|---|
| NEXIMMUNE, INC. | Director/Board Member | 01.01.2017 |
Ehemalige bekannte Positionen von Paul D'Angio
| Unternehmen | Position | Ende |
|---|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Corporate Officer/Principal | 01.06.2020 |
Edge Therapeutics, Inc.
 Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | Corporate Officer/Principal | 01.03.2019 |
| CELGENE | Corporate Officer/Principal | - |
Ausbildung von Paul D'Angio
| Duquesne University of The Holy Spirit | Undergraduate Degree |
| Seton Hall University School of Law | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| NEXIMMUNE, INC. | Health Technology |
| PDS BIOTECHNOLOGY CORPORATION | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | Health Technology |
